Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter (COSA)

Hannover Medical School (MHH)

Status: Unknown

Conditions: COVID-19

Treatments: Device: Seraph 100

Study type: Observational

Funder types: Other

Identifiers

NCT04361500

COSA-8998

Details and patient eligibility

About

The purpose of this registry study is to investigate the effectiveness and safety of the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) in the treatment of COVID-19 patients.

Full description

During the ongoing COVID-19 pandemic, millions of people have been infected with SARS- Cov-2 worldwide. In the absence of an approved vaccine or medical treatment, there is an emerging need for treatment options, especially in critically ill patients. Multiple pharmacological and non-pharmacological therapies are being investigated. In 2019, the Seraph® 100 Microbind® Affinity Blood Filter (ExThera Medical Corporation, CA, USA) was approved for the removal of pathogens in Europe. On April 17th the FDA granted Authorization for Emergency Use in patients with COVID-19 admitted to the ICU with confirmed or imminent respiratory failure.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• COVID-19 infection
• Treatment with the Seraph® 100 Microbind® Affinity Blood Filter
• Voluntary consent to participate in Registry

Exclusion criteria

• none

Trial design

100 participants in 1 patient group

COVID-19 patients with Seraph 100 therapy

Treatment:

Device: Seraph 100